famotidine / Generic mfg. - LARVOL DELTA

Proton Pump Inhibitor-Associated Hypomagnesemia Presenting as Syncope and Stroke Mimic (ACG 2026) - "Case Description/ We present a 67-year-old male with hypertension, type 2 diabetes mellitus, and chronic gastroesophageal reflux disease on long-term omeprazole who presented with nausea, dry heaving, dizziness, generalized weakness, and a syncopal episode...He was discharged with instructions to avoid PPIs, use famotidine for his symptoms, and follow closely with repeat outpatient lab monitoring...Early recognition is key, as stopping PPI use and correcting electrolyte levels can prevent recurrence and serious cardiac and neurologic complications. Figure: Magnesium trend Figure: Potassium, Calcium trend"

Cardiovascular • Diabetes • Endocrine Disorders • Gastroenterology • Gastroesophageal Reflux Disease • Hypertension • Metabolic Disorders • Type 2 Diabetes Mellitus

When Acid Suppression Fails: Isolated Hepatic Artery Vasculitis Masquerading as Refractory GERD (ACG 2026) - "Case Description/ A 54-year-old male with refractory GERD on esomeprazole and famotidine, Schatzki ring, obesity, and MASLD presented with chest pain radiating to the back and epigastric pain radiating to the right and left upper quadrants...The patient was treated with high-dose prednisone on a 12-week taper...No aortic or aortic branch involvement was identified. Figure: CT abdomen with contrast (coronal view) obtained 3 years prior to diagnosis showing normal caliber and wall thickness of the common hepatic artery (red arrow) without evidence of perivascular inflammation, serving as a baseline comparison and confirming the de novo development of vasculitis identified on subsequent imaging."

Cardiovascular • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Genetic Disorders • Inflammation • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Vasculitis

A Rare Cause of Gastric Outlet Obstruction: Duodenal Adenosquamous Carcinoma (ACG 2026) - "She had been taking Famotidine, Pantoprazole, and Sucralfate with minimal improvement. Figure: Heterogenous enhancing tumor in the first portion of the duodenum leading to gastric outlet obstruction. Figure: Endoscopic view of large extrinsic bulge into pre-pyloric region"

Colorectal Cancer • Dyspepsia • Endocrine Disorders • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Hepatology • Hypertension • Melanoma • Metabolic Disorders • Oncology • Small Intestinal Carcinoma • Solid Tumor

When Crohn's Isn't Crohn's: Cryptosporidiosis Masquerading as Inflammatory Bowel Disease on Cross-Sectional Imaging (ACG 2026) - "She presented two days earlier and was discharged on famotidine and ondansetron without improvement...Empiric intravenous methylprednisolone and piperacillin-tazobactam were initiated along with supportive care...Figure: Axial contrast-enhanced CT demonstrating terminal ileal and ileocecal bowel wall thickening with surrounding inflammatory fat stranding (red arrows), consistent with ileocolitis. Figure: Coronal contrast-enhanced CT showing inflammatory mural thickening and edema involving the terminal ileum and ileocecal region with adjacent mesenteric inflammatory changes (red arrows)."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease

Hidden Beneath an Ulcer: Invasive Mucormycosis Presenting as a Large Anastomotic Ulcer (ACG 2026) - "A 6-week course of liposomal amphotericin B and posaconazole (later transitioned to isavuconazole) was initiated, alongside pantoprazole 40 mg twice daily, and famotidine. Early biopsy with fungal staining is critical, as mucormycosis carries high mortality risk without prompt initiation of antifungal therapy and surgical intervention when possible. Gastrointestinal mucormycosis can be successfully managed medically with early recognition and a multidisciplinary approach."

Endocrine Disorders • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Pneumonia • Respiratory Diseases • Septic Shock

Esophageal Lichen Planus - A Rare Cause of Dysphagia (ACG 2026) - "She was advised to take famotidine which did not improve her dysphagia...It was due to strictures from chronic inflammation caused by ELP in which endoscopic dilation led to improvement in dysphagia. Figure: Esophageal stricture Figure: Sloughing of esophageal mucosa with stricture"

Cough • Dermatology • Dermatopathology • Eosinophilic Esophagitis • Esophageal Squamous Cell Carcinoma • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Lichen Planus • Otorhinolaryngology • Respiratory Diseases • Squamous Cell Carcinoma

Heartburn Meets Heart Block: Acute Esophageal Necrosis After Pacemaker Implantation (ACG 2026) - "However, over the preceding several months, his reflux symptoms progressively worsened becoming refractory to famotidine...This reinforces the importance of early recognition and management in patients with multiple risk factors. Figure: EGD findings (from left to right): GE junction, mid esophagus, distal esophagus"

Cardiovascular • Diabetes • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hypertension • Metabolic Disorders • Peripheral Arterial Disease

When GERD Is Not GERD: Unmasking Multisite EGID (ACG 2026) - "She was treated with Omeprazole 40 mg twice daily, famotidine 10 mg daily, and montelukast 10 mg daily, though she frequently missed omeprazole doses...Oral open capsule budesonide 9 mg daily was added, with partial symptom improvement...Further, dupilumab achieved symptomatic, laboratory, and endoscopic remission across all involved sites. Figure: Gastric ulcers of index EGD Figure: Duodenal ulcer of index EGD"

Eosinophilia • Eosinophilic Esophagitis • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Peptic Ulcer

Atypical Endoscopic Findings of HSV Esophagitis in an Immunocompetent Patient (ACG 2026) - "She is initially treated with famotidine without significant symptomatic relief...Patient is treated with pantoprazole and sucralfate and referred to infectious disease...Early recognition is important because antiviral therapy with acyclovir or valacyclovir may shorten symptom duration and accelerate recovery. Figure: Image 1: Upper endoscopy showing erosive esophagitis at the distal esophagus, with pathology later revealing HSV esophagitis. Figure: Image 2: Another endoscopic view of the HSV esophagitis."

Clinical • CNS Disorders • Epilepsy • Gastrointestinal Disorder • Herpes Simplex • Infectious Disease • Inflammation

When Parasites Play Cancer: Entamoeba Histolytica Colitis Simulating Cecal Malignancy â a Case Report (ACG 2026) - "At primary care and gastroenterology visits, he reported epigastric pain worsened by vinegar, relieved by famotidine, plus bloating and tenesmus...Luminal therapy like paromomycin is effective, highlighting the need for broad differentials in bloody diarrhea with colonic lesions to avoid escalation and improve outcomes. Figure: Initial Endoscopic and 1 year follow up"

Case report • Clinical • Colorectal Cancer • Eosinophilia • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Neutropenia • Oncology • Thrombocytosis

When Tetrads Take Over: Sarcina ventriculi In a Pediatric Patient With Chronic Gastrointestinal Symptoms (ACG 2026) - "Initial gastroenterology management included dietary modification with increased fiber and hydration, daily polyethylene glycol, famotidine, and hyoscyamine as needed...Recognition of this organism is important in pediatric patients with persistent gastrointestinal symptoms, and further research is needed to clarify its clinical significance and guide management. Figure: Image A: Sarcina Ventriculi tetrads in gastric tissue Image B: Sarcina Ventriculi tetrads high power Figure: Image C: Phytobezoar in stomach Image D: Close up image of Phytobezoar in stomach"

Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Pediatrics • Respiratory Diseases

Proton Pump Inhibitors Versus Famotidine and Infection or Hepatic Encephalopathy in Cirrhosis (ACG 2026) - " In the TriNetX US Collaborative Network, adults with cirrhosis and an acid-suppression indication who newly initiated a PPI or famotidine on or after January 1, 2021 (postdating the 2020 ranitidine withdrawal), following a 365-day washout of both to define new use, were propensity-score matched 1:1 on 30 baseline covariates (maximum standardized mean difference 0.075). The primary outcome was a 1-year composite of infection (SBP, Clostridioides difficile, or pneumonia) or medication-anchored hepatic encephalopathy (a diagnosis code plus lactulose or rifaximin, to improve coding validity)... Among 14,785 matched pairs, the primary infection/HE composite was null (HR 0.99, 95% CI 0.95-1.03), stable from 30 to 730 days, and also null in a broader within-platform network. Pneumonia, C. difficile, all-cause death, and liver transplant were null. Incident SBP was elevated (HR 1.33, 95% CI 1.09-1.61), persisted with the first 30 days excluded (1.33, 1.05-1.69), and remained..."

CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatology • Immunology • Infectious Disease • Pneumonia • Respiratory Diseases

A Malignant Mimic: HSV Esophagitis in an Immunocompetent Patient (ACG 2026) - "He was started on Valacyclovir, pantoprazole, and famotidine. Endoscopic biopsy can establish a treatable diagnosis and help avoid unnecessary oncologic evaluation. Figure: Nodular mucosa at the GE junction (left), LA Grade D esophagitis (right) Figure: Circumferential distal esophageal wall thickening with paraesophageal lymphadenopathy (left), Immunohistochemical stain for HSV-1 highlights the virally infected squamous cells (right)"

Clinical • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Cancer • Gastrointestinal Disorder • Herpes Simplex • Human Immunodeficiency Virus • Immunology • Infectious Disease • Solid Tumor • Vitiligo

A complementary dual-platform analytical strategy for resolving matrix effects and stability limitations in bioanalysis. (PubMed, Front Vet Sci) - "The complementary use of HPLC and UHPLC-MS/MS provided both characterization of compound-specific analytical behavior and sensitive quantification of trace drug concentrations in equine plasma. This analytical framework may support pharmacokinetic studies of famotidine and omeprazole in equine models."

Journal

Discovering repurposable drugs for Alzheimer's disease and related dementias: target trial emulation using decentralised real-world data. (PubMed, EBioMedicine) - "20 widely used medications may be associated with reduced progression from MCI to ADRD and represent promising candidates for clinical evaluation as repurposed therapies for dementia."

Journal • Real-world evidence • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Pain

Association Between Gastroesophageal Reflux and Post-Tympanostomy Tube Otorrhea in Children (AAO-HNSF 2026) - "GER was associated with increased rates of otorrhea following tympanostomy tube placement in children, suggesting reflux management as a modifiable factor in perioperative management."

Clinical • Allergic Rhinitis • Asthma • Gastroenterology • Gastroesophageal Reflux Disease • Immunology • Inflammation • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Conformational flexibility governs phosphate-induced solubility enhancement: a comparative study of cimetidine and famotidine by pH-dependent dissolution, NMR titration, DOSY, and DFT analysis. (PubMed, Eur J Pharm Biopharm) - "DFT-based Boltzmann analysis reveals that CIM possesses a broad low-energy conformer ensemble (partition function Z = 2.62), whereas FAM is dominated by a single rigid geometry (Z = 1.10). The correlation between conformational entropy and phosphate-induced solubility enhancement suggests that molecular flexibility is a key determinant of ion-specific buffer effects, with implications for BCS solubility classification using phosphate-buffered media."

Journal

Efficient determination of ranitidine, famotidine, and cimetidine in environmental and biological matrices using a NH₂-bimetallic MIL-88(Fe/Ni)@SiO₂/Fe₃O₄ composite and dispersive micro solid-phase extraction. (PubMed, Anal Bioanal Chem) - "The method was successfully applied to tap, river, and well water, as well as human urine samples, achieving excellent relative recovery rates (89.8-95.3%), even in samples from individuals who had ingested the drugs. The adsorbent could be reused for three cycles without significant loss in performance."

Journal

Enhanced Solubility of Famotidine through Salification. (PubMed, Cryst Growth Des) - "All salts exhibited good thermal and benchtop stability, and a six- to 20-fold increase in aqueous solubility was achieved, depending on the coformer used. The best performing salts include coformers on the FDA's generally recognized as safe list, making the solids promising for pharmaceutical applications."

Journal

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: University of Cincinnati | Phase classification: P ➔ P3 | N=100 ➔ 0 | Trial completion date: Aug 2021 ➔ Aug 2026 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Aug 2021 ➔ Aug 2026

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Trial withdrawal • Gastrointestinal Disorder

Empagliflozin protects against indomethacin-induced gastric injury in rats: evidence from inflammatory, apoptotic, and early PI3K/Akt/VEGF-related changes. (PubMed, Inflammopharmacology) - "Male Sprague-Dawley rats were divided into six groups: control, indomethacin, indomethacin + famotidine, indomethacin + empagliflozin (10 mg/kg), indomethacin + empagliflozin (20 mg/kg), and empagliflozin (20 mg/kg). Taken together, these findings indicate that empagliflozin exerts gastroprotective effects mainly through modulation of inflammatory and apoptotic pathways, with accompanying early changes in oxidative stress-related parameters and PI3K/Akt/VEGF-related signaling. These results suggest that empagliflozin may represent a potential candidate for the prevention of NSAID-induced gastric injury."

Journal • Preclinical • Diabetes • Inflammation • Metabolic Disorders • Pain • Type 2 Diabetes Mellitus • CASP3 • IL6 • TNFA • VEGFA

Anesthetic Management of a Patient with Systemic Mastocytosis: Navigating Perioperative Anaphylaxis Risk (ASA 2026) - "Premedication included famotidine, diphenhydramine, acetaminophen, and midazolam. Anesthesia was induced with fentanyl, propofol, rocuronium, and maintained with remifentanil and sevoflurane. Normothermia achieved with active warming. The perioperative course was uneventful without mast cell-mediated reactions."

Clinical • Cardiovascular • Hypertension • Immunology

Anaphylaxis to Sugammadex: an Atypical Presentation of a Rare Drug Allergy (ASA 2026) - "A 75-year-old woman developed hypotension, profound bradycardia, and skin flushing immediately following sugammadex administration after an uncomplicated lumbar laminectomy. However, her presentation resolved with atropine, diphenhydramine, and famotidine. The diagnosis was supported by an acute-to-baseline tryptase ratio of 6.1, surpassing the threshold which supports a diagnosis of anaphylaxis and makes non-IgE-mediated mimics less likely.3 Here, we discuss the underlying pathophysiology4 and emphasize the importance of recognizing atypical anaphylactic presentations to ensure appropriate management and medication avoidance."

Allergy • Cardiovascular • Hypotension • Immunology

Angioedema Without Anaphylaxis: An Atypical Presentation of Sugammadex Hypersensitivity After Pituitary Surgery (ASA 2026) - "The patient received antihistamines, steroids, and famotidine and remained intubated for airway protection. Angioedema resolved by postoperative day 1, allowing for safe extubation and discharge on postoperative day 2. This case highlights the importance of recognizing likely drug-associated angioedema as a presentation of hypersensitivity reactions."

Surgery • Cardiovascular • Immunology

CA230-1019: A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease (clinicaltrials.gov) - P1/2 | N=224 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Oct 2029 ➔ Nov 2027 | Trial primary completion date: Apr 2028 ➔ Jan 2027

First-in-human • Trial completion date • Trial primary completion date • Anemia • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • HP